A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Study ID
- NCT06760546
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Childhood-onset Combined Pituitary Hormone Deficiency
- Hypothalamic Obesity
- Multiple Pituitary Hormone Deficiency Genetic Form
- Optic Nerve Hypoplasia
- Pituitary Stalk Interruption Syndrome
- Septo-Optic Dysplasia
Eligibility Criteria
- Sex
- ALL
- Age
- 4 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Setmelanotide — DRUGSolution for daily subcutaneous injection
- Placebo — DRUGPlacebo matched to setmelanotide for daily subcutaneous injection
Study Details
This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how well setmelanotide works and how safe it is, patients with cHO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 26 weeks on a therapeutic regimen.
Key Dates
- Start date
- Sep 23, 2025
- Status verified
- Feb 2026
- Primary completion
- Mar 13, 2027
- Completion
- Mar 13, 2028
Study Design
- Enrollment
- 39 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: SetemelanotideRandomized 2:1 (Setmelanotide: Placebo)
- Placebo Comparator: PlaceboRandomized 2:1 (Setmelanotide: Placebo)
Primary Outcome Measure
Mean % change in BMI [ Time Frame: From Baseline after 26 weeks on a therapeutic regimen ]
Central Contacts
- Rhythm Clinical Trials(857) 264-4280
- Physician Inquiry Clinical Trials(857) 264-4280
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35233 | - |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | - |
| Lurie Children's Hospital | Chicago | Illinois | 60611 | - |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | - |
| Children's Minnesota | Saint Paul | Minnesota | 55102 | - |
| Columbia University Irving Medical Center | New York | New York | 10032 | - |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | - |
| Seattle Children's Research Institute | Seattle | Washington | 98105 | - |
Find similar trials in Birmingham, AL
Related Studies
- A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentPHASE1/PHASE2 · Recruiting · Rhythm Pharmaceuticals, Inc. · Birmingham, Alabama
- Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic ObesityPHASE2 · Recruiting · Seattle Children's Hospital · Philadelphia, Pennsylvania
- Tirzepatide in PWS, HO and GNSOPHASE4 · Recruiting · Grace Kim · Saint Paul, Minnesota
- A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)PHASE2 · Enrolling By Invitation · Rhythm Pharmaceuticals, Inc. · Aurora, Colorado